424 related articles for article (PubMed ID: 25295534)
21. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
Fettke H; Kwan EM; Bukczynska P; Steen JA; Docanto M; Ng N; Parente P; Mant A; Foroughi S; Pezaro C; Hauser C; Nguyen-Dumont T; Southey MC; Azad AA
Prostate; 2021 Sep; 81(13):992-1001. PubMed ID: 34254334
[TBL] [Abstract][Full Text] [Related]
22. MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT.
Shen T; Wang W; Zhou W; Coleman I; Cai Q; Dong B; Ittmann MM; Creighton CJ; Bian Y; Meng Y; Rowley DR; Nelson PS; Moore DD; Yang F
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586682
[TBL] [Abstract][Full Text] [Related]
23. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
24. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
25. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.
Zacharias N; Lee J; Ramachandran S; Shanmugavelandy S; McHenry J; Dutta P; Millward S; Gammon S; Efstathiou E; Troncoso P; Frigo DE; Piwnica-Worms D; Logothetis CJ; Maity SN; Titus MA; Bhattacharya P
Mol Imaging Biol; 2019 Feb; 21(1):86-94. PubMed ID: 29748904
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
27. ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
[TBL] [Abstract][Full Text] [Related]
28. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
Ono M; Oka S; Okudaira H; Nakanishi T; Mizokami A; Kobayashi M; Schuster DM; Goodman MM; Shirakami Y; Kawai K
Nucl Med Biol; 2015 Nov; 42(11):887-92. PubMed ID: 26278491
[TBL] [Abstract][Full Text] [Related]
29. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
30. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
[TBL] [Abstract][Full Text] [Related]
31. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
32. Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
Brown NE; Jones A; Hunt BG; Waltz SE
Prostate; 2022 Nov; 82(15):1422-1437. PubMed ID: 35860905
[TBL] [Abstract][Full Text] [Related]
33. Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.
Xie Y; Lu W; Liu S; Yang Q; Carver BS; Li E; Wang Y; Fazli L; Gleave M; Chen Z
Mol Endocrinol; 2014 Oct; 28(10):1629-39. PubMed ID: 25099011
[TBL] [Abstract][Full Text] [Related]
34. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.
Wang L; Song G; Chang X; Tan W; Pan J; Zhu X; Liu Z; Qi M; Yu J; Han B
Oncogene; 2015 Sep; 34(36):4735-45. PubMed ID: 25500540
[TBL] [Abstract][Full Text] [Related]
35. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
[TBL] [Abstract][Full Text] [Related]
36. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
37.
Chen X; Ma J; Wang X; Zi T; Qian D; Li C; Xu C
Front Endocrinol (Lausanne); 2022; 13():1106175. PubMed ID: 36601001
[TBL] [Abstract][Full Text] [Related]
38. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
39. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
40. Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
Lubik AA; Nouri M; Truong S; Ghaffari M; Adomat HH; Corey E; Cox ME; Li N; Guns ES; Yenki P; Pham S; Buttyan R
Int J Cancer; 2017 Jan; 140(2):358-369. PubMed ID: 27672740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
